

ZIBO EASTMED HEALTHCARE PRODUCTS CO., LTD CE TECHNICAL FILE

Sterile insulin syringes for single use

April, 2016

Prepared by:	Audited by:	Approved by:	

Table of Contents

1 General

- 1.1 Company Profile
- **1.2 Product Description and Intended Use**
- **1.3 Classification**
- **1.4 Conformity Assessment Procedure**
- **1.5 Manufacturer and EC Authorized Representative**
- 2 EC Declaration of Conformity
- **3 Description of the product and production process**
- 4 Labelling
- **5 Instruction for Use**
- **6 Applied Standard**
- **7 Essential Requirements Checklist**
- 8 Risk Analysis
- 9Test report
- 10 Sterile method and validation
- **11 Packaging Verification**
- **12 Clinical Data**
- **13 Control Procedure of Vigilance System**

1 General

1.1 Company Profile

Zibo Eastmed Healthcare Products Co., Ltd. is a professional company in disposable medical device area and devotes itself to researching, exploiting and manufacturing an extensive range of medical devices and healthcare products such as: disposable syringes and needles, disposable infusion sets and blood transfusion sets, gloves, airway management, feeding and drainage tubes, IV therapy and vascular access products, wound care products, products for urology, nonwoven products and surgical products. Accuracy, professionalism, efficiency are exactly what you can expect from us. As evidence of our efforts, our facilities have obtained ISO13485 certification and our products have received CE certification. It allows our medical goods to meet standards approved all over the world: South Asia, Middle East, Europe, South and Central America as well as Africa. We deliver the highest quality service and products with professionalism, knowledge and personal attention. We are always upgrading the product design and quality using advanced manufacturing technologies to satisfy your demands.

1.2 Products description and intended use

The product is applicable for human body injection immediately after insulin medicine aspiration.

1.3 Classification

Base on intended use and definition of categorization, and according to 93/42/EEC, Annex IX, rule 6, this product is in Class II a.

1.4 Conformity Assessment Procedure

According to 93/42/EEC, the conformity assessment procedure of annex IX is applicable to this product.

1.5 Manufacturer and EC Authorized Representative

The information about manufacturer

Manufacturer: Zibo Eastmed Healthcare Products Co., Ltd.

Address: No.118 Huaguang Road, Zhangdian District, Zibo 255000, Shandong China Tel: +86-533-5201297 Fax: +86-533-5201298 WEB: http://www.eastmedcn.com/

European Authorized Representative info.:

Humiss Beratung GmbH Address: Gneisenaustraße 8 40477 Düesseldorf, Germany E-mail:sungo.group@yahoo.com

2 EC Declaration of Conformity

CE Tashnigal Eila, Starila inqulin	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin	Revision	Rev. A/0
syringes for single use	Page	4 of 43

EC Declaration of Conformity

Manufacturer: Zibo Eastmed Healthcare Products Co., Ltd. Address: Zhangdian District, Zibo City, Shandong Province, China

whose single Authorized Representative: SUNGO Certification Company Limited Address: RM101, MAPLE HOUSE, 118 HIGH STREET, PURLEY, LONDON, ENGLAND

We, the manufacturer, herewith declare that the products

Sterile insulin syringes for single use

UMDNS-Code: 13941

meet the provisions of Directive 93/42/EEC which apply to them.

The medical device has been assigned to class IIa according to Annex IX of the Directive 93/42/EEC. It bears the mark

CE

The product concerned has been manufactured under a quality management system according to Annex IX of Directive 93/42/EEC.

Compliance of the designated product with the Directive 93/42/EEC has been assessed and certified by the Notified Body

TÜV Rheinland LGA Products GmbH Tillystraße 2, 90431, Nürnberg, Germany

Certificate No.: Issue date: Expiry date:

following the procedure relating to the EC Declaration of Conformity set out in Annex IX of Directive 93/42/EEC.

This Declaration of conformity is valid in connection with the release document for the respective batch of produced devices.

The above mentioned declaration of conformity is exclusively under the responsibility of

Company: Zibo Eastmed Healthcare Products Co., Ltd. Address: No.118 Huaguang Road, Zhangdian District, Zibo 255000, Shandong China

Place, date

Legally binding signature, Function

CE Technical File Starile inculin	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin	Revision	Rev. A/0
syringes for single use	Page	5 of 43

3.1 Intended use

The product is applicable for human body injection immediately after insuline medicine aspiration.

3.2 Structure and material

Sterile insulin syringes for single use is composed by barrel, plunger, piston, needle, big and small cap. The raw material of barrel and plunger is PP; and of needle tube is SUS304; and of piston is natural rubber or latex free.

Main material includes: PP, needle tube, natural rubber;


Auxiliary material includes: medical active silicone.


Main material			Auxiliary material		
Serial No.	Components name	Raw material	Serial No. Raw material		
01	Barrel	PP	01 Dimethyl silicone		
02	Plunger	PP	02 Glue		
03	Piston	Natural rubber, latex free			
04	cannula	SUS304			
05	Protective cap				

3.3 Picture



3.4 production process







Note: 1. this chart is the process flow chart of sterile disposable insuline syringe; 2. the green part is the 100,000 class cleaning area; 3. the out-sourced components includes dialyzing paper, PP/PE medical use packaging film, dimethyl silicone; 4. injection and printing are the control points of the critical processes; 5. single packing and sterilization are the special processes.


4 Labelling

	DATE OF MANUFACTURE		Manufacturer	
\otimes	Do not reuse	LOT	Batch code	
STERILEEO	Sterilized using Ethylene Oxide	Λ	Warning, please refer to the instructions in the annex	
	Do not use if package is damaged		Consulting Instructions for use	
EC REP	Authorized representative in the European Community	C € ₀₁₉₇	The product meets the basic requirements of European medical devices directive 93/42/EEC	


CE Technical File Starile inculin	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin	Revision	Rev. A/0
syringes for single use	Page	7 of 43

Sample for package labelling:

Primary package:




Middle package:



CE Technical File Starile inculin	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin	Revision	Rev. A/0
syringes for single use	Page	8 of 43

Outer package:



syringes for single use

5 Instruction for Use

User Manual

[Product Name] Sterile insulin syringes for single use

The Sterile insulin syringes for single use is applicable for human body injection immediately after insulin medicine aspiration.

[Specification]

1ml, 0.5ml, 0.3ml, needle specifications 0.25 (31G), 0.3 (30G), 0.33 (29G), 0.36 (28G)

[Structure and Character]

1. This product is made of barrel, plunger, piston, needle and big and small cap.

2. Syringe sterilized by EO, should be sterile, non-toxic, pyrogen-free, non-hemolytic reaction.

[Methods]

It's can be used after opening, aspirate the fluid, expel up the air, then can be used for injection.

/ [Notice]

1. This product is sterilized by Ethylene oxide, sterility, non-pyrogen;

2. Before use, please check the integrity of the single packing, if any leakage, damage and the drop off of the protective cap, please do not use;

3. This product is sterilized and can be used only for once, please destroy after use, the waste shall be disposed according to local government's regulations;

4. This product cannot be used together with paraldehyde;

5. The operation shall be implemented and warded by professional nursing staff;

6. The valid period of the product is 3 years after EO sterilization, during use, please read clearly the expiry date at the sealing of the single packing, please do not use after the valid date.

7. The injection part shall choose the loose part of the skin, such as arm, leg, hip and belly, and the injection part shall alternate, the same part cannot be injected for 2 times within 2 weeks, and every time's injection part shall be at least 1cm from last time.

[Shelf life] 3 years

[Storage] 1. During transportation, the product shall be prevented from great pressure, direct sunlight and rain and snow;

2. The product shall be stored indoors with the humidity no more than 80%, without corrosive gas, cool, dry and well-ventilated.

Zibo Eastmed Healthcare Products Co., Ltd. No.118 Huaguang Road, Zhangdian District, Zibo 255000, Shandong China











Humiss Beratung GmbH Address: Gneisenaustraße 8 40477 Düesseldorf, Germany

CE Technical File Starile inculin	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin	Revision	Rev. A/0
syringes for single use	Page	10 of 43

6 Applied Standard

ltem	Standard	Revision	Description	
1	MDD93/42/EEC including Directive 2007/47/EC	2007	Medical Device Directive	
2	EN ISO13485	2016	Quality system—Medical devices-Particular requirements	
3	EN ISO14971	2012	Medical Device Application of Risk Management in Medical Device	
4	EN ISO 15223-1	2012	Medical devices. Symbols to be used with medical device labels, labelling and information to be supplied General requirements.	
5	EN1041	2008	Terminology, Symbols and Information Related to Medical Devices –Information Provided by Manufacturers of Medical Devices	
6	EN 556-1	2001/ AC:2006	Sterilization of medical devices - Requirements for medical devices to be designated "STERILE" - Part 1: Requirements for terminally sterilized medical devices	
7	EN ISO10993-1	2010	Biological Evaluation of Medical Device – Part 1: Test & Evaluation	
8	EN ISO10993-5	2009	Biological Evaluation of Medical Device – Part 5: Cytoxicity Test – in vitro method	
9	EN ISO10993-7	2008	Biological evaluation of medical devices - Part 7: Ethylene oxide sterilization residuals	
10	EN ISO10993-10	2010	Biological Evaluation of Medical Device –Part 10: Irritation and Sensitization Test	

CE Technical File Starile inculin	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin	Revision	Rev. A/0
syringes for single use	Page	11 of 43

11	EN ISO10993-11	2009	Biological evaluation of medical devices - Part 11: Tests for systemic toxicity
12	EN ISO11607-1	2009	Packaging for terminally sterilized medical devices - Part 1: Requirements for materials, sterile barrier systems and packaging systems
13	EN ISO11607-2	2006	Packaging for terminally sterilized medical devices - Part 2: Validation requirements for forming, sealing and assembly processes
14	ISO11137-1	2006	Sterilization of health care Products -Radiation : Requirement for development, validation and routine control of a sterilization process for medical devices
15	EN ISO11737-1	2009	Sterilization of medical devices - Microbiological methods - Part 1: Determination of a population of microorganisms on products
16	EN ISO11737-2	2009	Sterilization of medical devices - Microbiological methods - Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process
17	EN ISO11135	2014	Sterilization of health-care products Ethylene oxide Requirements for the development, validation and routine control of a sterilization process for medical devices
18	EN ISO11608-2	2000	Pen-injectors for medical use-Part2: Needles-Requirements and test methods
19	ENISO8537	2007	Sterile disposable insulin syringe

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	12 of 43

7 Essential Requirements checklist

Summary: After checking the product in compliance to the Annex I Essential Requirements, relevant requirements are all met.

Cł	necklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
١.	GENERAL R	REQU	IREMENTS		
1.	 The devices must be designed and manufactured in such a way that, when used under the conditions and for the purposes intended, they will not compromise the clinical condition or the safety of patients, or the safety and health of users or, where applicable, other persons, provided that any risks which may be associated with their intended use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety. This shall include: reducing, as far as possible, the risk of use error due to the ergonomic features of the device and the environment in which the device is intended to be used (design for patient safety), and consideration of the technical knowledge, experience, education and training and where applicable the medical and physical conditions of intended users (design for lay, professional, disabled or other users). 	A	ISO14971	JC/WI7.1c/06 Risk management report of disposable insulin syringe	ok
2.	 The solutions adopted by the manufacturer for the design and construction of the devices must conform to safety principles, taking account of the generally acknowledged state of the art. In selecting the most appropriate solutions, the manufacturer must apply the following principles in the following order: eliminate or reduce risks as far as possible (inherently safe design and construction), where appropriate take adequate protection measures including 	A	ISO14971 EN ISO15223-1 EN1041	Product packaging chart JC/DWRYDS-01-B	ok

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	13 of 43

Ch	ecklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
	alarms if necessary, in relation to risks that cannot be eliminated,				
	 Inform users of the residual risks due to any shortcomings of the protection measures adopted. 				
3.	The devices must achieve the performances intended by the	А	ISO11607-1	Process validation report of the blister	ok
	manufacturer and be designed, manufactured and packaged in such a way that they are suitable for one or more of the functions referred to in Article 1 (2) (a), as specified by the manufacturer.		ISO11607-2:	packing machine JC/WI7.4b/01	
4.	The characteristics and performances referred to in sections 1, 2 and 3 must not be adversely affected to such a degree that the clinical condition and safety of the patients and, where applicable, of other persons are compromised during the lifetime of the device as indicated by the manufacturer, when the device is subjected to the stresses which can occur during normal conditions of use.	A	ISO14971	JC/WI7.1c/06 Risk management report of disposable insulin syringe	ok
5.	The devices must be designed, manufactured and packed in such a way that their characteristics and performances during their intended use will not be adversely affected during transport and storage taking account of the instructions and information provided by the manufacturer.	A	ISO14971	JC/WI7.1c/06 Risk management report of disposable insulin syringe	ok
6.	Any undesirable side effects must constitute an acceptable risk when weighed against the performances intended.	A	ISO14971	JC/WI7.1c/06 Risk management report of disposable insulin syringe	ok
6a.	Demonstration of conformity with the essential requirements must include a clinical evaluation in accordance with Annex X.	A	ISO14155	Clinical report	ok
Π.	REQUIREMENTS REGARDIN	G DE	SIGN AND CONSTRUCTION	·	
7.	Chemical, physical and biological properties				

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	14 of 43

Ch	Checklist according to annex I of the Medical Device Directive (MDD)			Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
7.1	 The devices must be designed and manufactured in such a way as to guarantee the characteristics and performances referred to in Section 1 on the "General requirements". Particular attention must be paid to: the choice of materials used, particularly as regards toxicity and, where appropriate flammability, the compatibility between the materials used and biological tissues, cells and body fluids, taking account of the intended purpose of the device. Where appropriate, the results of biophysical or modelling research whose validity has been demonstrated beforehand. 	A	ISO8537 ISO10993-1 ISO10993-11	Insulin syringe leaving-factory inspection report Disposable syringe product test report Type 2010ZC No. 973	ok
7.2	The devices must be designed, manufactured and packed in such a way as to minimise the risk posed by contaminants and residues to the persons involved in the transport, storage and use of the devices and to the patients, taking account of the intended purpose of the product. Particular attention must be paid to the tissues exposed and the duration and frequency of the exposure.				
7.3	The devices must be designed and manufactured in such a way that they can be used safely with the materials, substances and gases with which they enter into contact during their normal use or during routine procedures; if the devices are intended to administer medicinal products they must be designed and manufactured in such a way as to be compatible with the medicinal products concerned according to the provisions and restrictions governing those products and that their performance is maintained in accordance with the intended use.				
7.4	Where a device incorporates, as an integral part, a substance which, if used separately, may be considered to be a medicinal product as defined in Article 1 of Directive 2001/83/EC and which is liable to act upon the body with action ancillary to that of the device, the quality, safety and usefulness of the substance must be verified by analogy with				

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	15 of 43

Checklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
the methods specified in Annex I to Directive 2001/83/EC.				
For the substances referred to in the first paragraph, the notified body shall, having verified the usefulness of the substance as part of the medical device and taking account of the intended purpose of the device, seek a scientific opinion from one of the competent authorities designated by the Member States or the European Medicines Agency (EMEA) acting particularly through its committee in accordance with Regulation (EC) No 726/2004 ¹ on the quality and safety of the substance including the clinical benefit/risk profile of the incorporation of the substance into the device. When issuing its opinion, the competent authority or the EMEA shall take into account the manufacturing process and the data related to the usefulness of incorporation of the substance into the device by the notified body.				
Where a device incorporates, as an integral part, a human blood derivative, the notified body shall, having verified the usefulness of the substance as part of the medical device and taking into account the intended purpose of the device, seek a scientific opinion from the EMEA, acting particularly through its committee, on the quality and safety of the substance including the clinical benefit/risk profile of the incorporation of the human blood derivative into the device. When issuing this opinion, the EMEA shall take into account the manufacturing process and the data related to the usefulness of incorporation of the substance into the device as determined by the notified body. Where changes are made to an ancillary substance incorporated in a device, in particular related to its manufacturing process, the notified body shall be informed of the changes and shall consult the relevant medicines competent authority (i.e. the one involved in the initial consultation), in order to confirm that the quality and safety of the ancillary substance are maintained. The competent authority shall take	NA			

¹ Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1). Regulation as last amended by Regulation (EC) No 1901/2006.

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	16 of 43

Che	ecklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
	into account the data related to the usefulness of incorporation of the substance into the device as determined by the notified body, in order to ensure that the changes have no negative impact on the established benefit/risk profile of the addition of the substance in the medical device.				
	When the relevant medicines competent authority (i.e. the one involved in the initial consultation) has obtained information on the ancillary substance, which could have an impact on the established benefit/risk profile of the addition of the substance in the medical device, it shall provide the notified body with advice, whether this information has an impact on the established benefit/risk profile of the addition of the substance in the medical device or not. The notified body shall take the updated scientific opinion into account in reconsidering its assessment of the conformity assessment procedure.				
7.5	The devices must be designed and manufactured in such a way as to reduce to a minimum the risks posed by substances leaking from the device. Special attention shall be given to substances which are carcinogenic, mutagenic or toxic to reproduction, in accordance with Annex I to Council Directive 67/548/EEC ² of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances ³ .	NA			
	If parts of a device (or a device itself) intended to administer and/or remove medicines, body liquids or other substances to or from the body, or devices intended for transport and storage of such body fluids or substances, contain phthalates which are classified as carcinogenic, mutagenic or toxic to reproduction, of category 1 or 2, in accordance with Annex I to Directive 67/548/EEC, these devices must be labelled on the device itself and/or on the packaging for each unit or, where appropriate, on the sales packaging as a device containing phthalates.	NA			

 ² Internal note: replaced by (EC) 1272/2008
 ³ OJ 196, 16.8.1967, p. 1. Directive as last amended by Directive 2006/121/EC of the European Parliament and of the Council (OJ L 396, 30.12.2006, p. 850).

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	17 of 43

Che	ecklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
	If the intended use of such devices includes treatment of children or treatment of pregnant or nursing women, the manufacturer must provide a specific justification for the use of these substances with regard to compliance with the essential requirements, in particular of this paragraph, within the technical documentation and, within the instructions for use, information on residual risks for these patient groups and, if applicable, on appropriate precautionary measures.				
7.6	The devices must be designed and manufactured in such a way as to reduce as much as possible, risks posed by the unintentional ingress of substances into the device taking into account the device and the nature of the environment in which it is intended to be used.	A	ISO14971	JC/WI7.1c/06 Risk management report of disposable insulin syringe	ОК
8.	Infection and microbial contamination				
8.1	The devices and their manufacturing processes must be designed in such a way as to eliminate or reduce as far as possible the risk of infection to the patient, user and third parties. The design must allow easy handling and, where necessary, minimise contamination of the device by the patient or vice versa during use.	A	ISO11737-1 ISO11737-2 ISO14644-2	Environment test report of the cleaning room	ok
8.2	Tissues of animal origin must originate from animals that have been subjected to veterinary controls and surveillance adapted to the intended use of the tissues. Notified Bodies shall retain information on the geographical origin of the animals.	NA			
	Processing, preservation, testing and handling of tissues, cells and substances of animal origin must be carried out so as to provide optimal security. In particular safety with regard to viruses and other transmissible agents must be addressed by implementation of validated methods of elimination or viral inactivation in the course of the manufacturing process.				

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	18 of 43

Che	ecklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
8.3	Devices delivered in a sterile state must be designed, manufactured and packed in a non-reusable pack and/or according to appropriate procedures to ensure they are sterile when placed on the market and remain sterile, under the storage and transport conditions laid down, until the protective packaging is damaged or opened.	A	EN ISO15223-1 EN1041	Product usage instruction	ОК
8.4	Devices delivered in a sterile state must have been manufactured and sterilised by an appropriate, validated method.	A	ISO11135-1	Ethylene oxide sterilization validation report JC/WI7.5.2e/01、JC/WI7.5.2e/02	ОК
8.5	Devices intended to be sterilised must be manufactured in appropriately controlled (e.g. environmental) conditions.	A	ISO11737-1 ISO11737-2 ISO14644-2	Environment test report of the cleaning room	ОК
8.6	Packaging systems for non-sterile devices must keep the product without deterioration at the level of cleanliness stipulated and, if the devices are to be sterilised prior to use, minimise the risk of microbial contamination. The packaging system must be suitable taking account of the method of sterilisation indicated by the manufacturer.	NA			
8.7	The packaging and/or label of the device must distinguish between identical or similar products sold in both sterile and non-sterile condition.	A	ISO14971 EN ISO15223-1 EN1041	Product packaging chart JC/DWRYDS-01-B	ОК
9.	Construction and environmental properties				
9.1	If the device is intended for use in combination with other devices or equipment, the whole combination, including the connection system must be safe and must not impair the specified performance of the devices. Any restrictions on use must be indicated on the label or in	NA			

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	19 of 43

Checklist according to annex I of the Medical Device Directive (MDD)		A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
	the instruction for use.				
9.2	Devices must be designed and manufactured in such a way as to remove or minimise as far as possible:	NA			
	• the risk of injury, in connection with their physical features, including the volume/pressure ratio, dimensional, and where appropriate the ergonomic features,				
	• risks connected with reasonably foreseeable environmental conditions, such as magnetic fields, external electrical influences, electrostatic discharge, pressure, temperature or variations in pressure, and acceleration,				
	• the risks of reciprocal interference with other devices normally used in the investigations or for the treatment given,				
	• risks arising where maintenance or calibration are not possible (as with implants) from ageing of the materials used or loss of accuracy of any measuring or control mechanism.				
9.3	Devices must be designed and manufactured in such a way as to minimise the risks of fire or explosion during normal use and in single fault condition. Particular attention must be paid to devices whose intended use includes exposure to flammable substances which could cause combustion.	NA			
10.	Devices with a measuring function				
10.1	Devices with a measuring function must be designed and manufactured in such a way as to provide sufficient accuracy and stability within appropriate limits of accuracy and taking account of the intended purpose of the device. The limits of accuracy must be indicated by the	NA			

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	20 of 43

Che	ecklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
	manufacturer.				
10.2	The measurement, monitoring and display scale must be designed in line with ergonomic principles, taking account of the intended purpose of the device.	NA			
10.3	The measurements made by devices with a measuring function must be expressed in legal units conforming to the provisions of Council Directive 80/181/EEC ⁴ .	NA			
11.	Protection against radiation				
11.1 11.1.1	<i>General</i> Devices shall be designed and manufactured such that exposure of patients, users and other persons to radiation shall be reduced as far as possible compatible with the intended purpose, whilst not restricting the application of appropriate specified levels for therapeutic and diagnostic purposes.	NA			
11.2 11.2.1	Intended radiation Where devices are designed to emit hazardous levels of radiation necessary for a specific medical purpose the benefit of which is considered to outweigh the risks inherent in the emission, it must be possible for the user to control the emissions. Such devices shall be designed and manufactured to ensure reproducibility and tolerance of relevant variable parameters.	NA			
11.2.2	Where devices are intended to emit potentially hazardous, visible and/or invisible radiation, they must be fitted, where practicable, with visual displays and/or audible warnings of such emissions.	NA			

⁴ OJ No L 39, 15. 2. 1980, p. 40. Directive as last amended by Directive 89/617/EEC (OJ No L 357, 7. 12. 1989, p. 28).

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	21 of 43

Che	cklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
11.3	Unintended radiation	NA			
11.3.1	Devices shall be designed and manufactured in such a way that exposure of patients, users and other persons to the emission of unintended, stray or scattered radiation is be reduced as far as possible.				
11.4	Instructions	NA			
11.4.1	The operating instructions for devices emitting radiation must give detailed information as to the nature of the emitted radiation, means of protecting the patient and the user and on ways of avoiding misuse and of eliminating the risks inherent in installation.				
11.5 11.5.1	<i>Ionising radiation</i> Devices intended to emit ionising radiation must be designed and manufactured in such a way as to ensure that, where practicable, the quantity, geometry and quality of radiation emitted can be varied and controlled taking into account the intended uses.	NA			
11.5.2	Devices emitting ionising radiation intended for diagnostic radiology shall be designed and manufactured in such a way, as to achieve appropriate image and/or output quality for the intended medical purpose whilst minimising radiation exposure of the patient and user.	NA			
11.5.3	Devices emitting ionising radiation intended for therapeutic radiology shall be designed and manufactured in such a way as to enable reliable monitoring and control of the delivered dose, the beam type and energy and where appropriate the quality of the radiation.	NA			
12.	Requirements for medical devices connected to or equipped with an energy source				
12.1	Devices incorporating electronic programmable systems must be designed to ensure the repeatability, reliability and performance of these systems according to their intended use. In the event of a single fault condition (in the system) appropriate means should be adopted to	NA			

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	22 of 43

Che	Checklist according to annex I of the Medical Device Directive (MDD)		A/ Standards, other directives and Documentation (test reported by protocols, literature or reading for no applicability)		Ok or failure
	eliminate or reduce as far as possible consequent risks				
12.1a	For devices which incorporate software or which are medical software in themselves, the software must be validated according to the state of the art taking into account the principles of development lifecycle, risk management, validation and verification.	NA			
12.2	Devices where the safety of the patients depends on an internal power supply must be equipped with a means of determining the state of the power supply.	NA			
12.3	Devices where the safety of the patient depends on an external power supply must include an alarm system to signal any power failure.	NA			
12.4	Devices intended to monitor one or more clinical parameters of a patient must be equipped with appropriate alarm systems to alert the user of situations which could lead to death or severe deterioration of the patient's state of health.	NA			
12.5	Devices must be designed and manufactured in such a way as to minimise the risks of creating electromagnetic fields which could impair the operation of other devices or equipment in the usual environment.	NA			
12.6	Protection against electrical risks Devices must be designed and manufactured in such a way as to avoid, as far as possible, the risk of accidental electric shocks during normal use and in single fault condition, provided that the devices are installed correctly.	NA			
12.7 12.7.1	Protection against mechanical and thermal risks Devices must be designed and manufactured in such a way as to protect the patient and user against mechanical risks connected with, for example, resistance, stability and moving parts.	NA			

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	23 of 43

Che	ecklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
12.7.2	Devices must be designed and manufactured in such a way as to reduce to the lowest possible level the risks arising from vibration generated by the devices, taking account of technical progress and of the means available for limiting vibrations, particularly at source, unless the vibrations are part of the specified performance.	NA			
12.7.3	Devices must be designed and manufactured in such a way as to reduce to the lowest possible level the risks arising from the noise emitted, taking account of technical progress and of the means available to reduce noise, particularly at source, unless the noise emitted is part of the specified performance.	NA			
12.7.4	The terminals and connectors to the electricity, gas or hydraulic and pneumatic energy supplies which the user has to handle must be designed and constructed in such a way as to minimise all possible risks.	NA			
12.7.5	Accessible parts of devices (excluding any parts or areas intended to supply heat or reach given temperatures) and their surroundings must not attain potentially dangerous temperatures under normal use.	NA			
12.8 12.8.1	Protection against the risks posed to the patient by energy supplies or substances Devices for supplying the patient with energy or substances must be designed and constructed in such a way that the flow rate can be set and maintained accurately enough to guarantee the safety of the patient and of the user.	NA			
12.8.2	Devices must be fitted with the means of preventing and/or indicating any inadequacies in the flow-rate which could pose a danger. Devices must incorporate suitable means to prevent, as far as possible, the accidental release of dangerous levels of energy from an energy and/or substance source.	NA			

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	24 of 43

Che	ecklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
12.9	The function of the controls and indicators must be clearly specified on the devices. Where a device bears instructions required for its operation or indicates operating or adjustment parameters by means of a visual system, such information must be understandable to the user and, as appropriate, the patient.	NA			
13.	Information supplied by the manufacturer				
13.1	Each device must be accompanied by the information needed to use it safely and properly, taking account of the training and knowledge of the potential users, and to identify the manufacturer. This information comprises the details on the label and the data in the instructions for use. As far as practicable and appropriate, the information needed to use the device safely must be set out on the device itself and/or on the packaging for each unit or, where appropriate, on the sales packaging. If individual packaging of each unit is not practicable, the information must be set out in the leaflet supplied with one or more devices. Instructions for use must be included in the packaging for every device. By way of exception, no such instruction leaflet is needed for devices in Class I or Class II a if they can be used completely safely without any such instructions.	A	EN ISO15223-1 EN1041	Product packaging chart JC/DWRYDS-01-B Product usage instruction	ok
13.2	Where appropriate, this information should take the form of symbols. Any symbol or identification colour used must conform to the harmonised standards. In areas for which no standards exist, the symbols and colours must be described in the documentation supplied with the device.	NA			

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	25 of 43

Ch	ecklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer		Ok or failure
13.3	 The label must bear the following particulars: a) the name or trade name and address of the manufacturer. For devices imported into the Community, in view of their distribution in the Community, the label, or the outer packaging, or instructions for use, shall contain in addition the name and address of the authorised representative where the manufacturer does not have a registered place of business in the Community; 	A	EN ISO15223-1 EN1041	Product packaging chart JC/DWRYDS-01-B	ok
	b) the details strictly necessary to identify the device and the contents of the packaging especially for the users;				
	c) where appropriate, the word "STERILE";	NA			
	d) where appropriate, the batch code, preceded by the word "LOT", or the serial number;	A	EN 1041 EN ISO 15223-1	Instruction of use, Label	ok
	e) where appropriate, an indication of the date by which the device should be used, in safety, expressed as the year and month;	A	EN ISO 15223-1	Label	ok
	f) where appropriate, an indication that the device is for single use. A manufacturer's indication of single use must be consistent across the Community;				
	g) if the device is custom made, the words "custom made device";	А			
	h) if the device is intended for clinical investigations, the words "exclusively for clinical investigations";				
	i) any special storage and/or handling conditions;				
	j) any special operating instructions;	А			
	k) any warnings and/or precautions to take;	A	EN ISO 15223-1	Product packaging chart JC/DWRYDS-01-B	ok

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	26 of 43

Che	ecklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
				Label	
	 I) year of manufacture of active devices other than those covered by e). This indication may be included in the batch or serial number; 	A	EN ISO 15223-1	Label	ok
	m) where applicable, method of sterilisation.	NA			
	n) in the case of a device within the meaning of Article 1(4a), an indication that the device contains a human blood derivative."				
13.4	If the intended purpose of the device is not obvious to the user, the manufacturer must clearly state it on the label and in the instructions for use.	A	EN ISO15223-1 EN1041	Product packaging chart JC/DWRYDS-01-B Product usage instruction	ok
13.5	Wherever reasonable and practicable, the devices and detachable components must be identified, where appropriate in terms of batches, to allow all appropriate action to detect any potential risk posed by the devices and detachable components.	NA			
13.6	Where appropriate, the instructions for use must contain the following particulars:	NA			
	a) the details referred to in 13.3, with the exception of d) and e)				
	b) the performances referred to in section 3 and any				
	undesirable side effects;				

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	27 of 43

Che	cklist according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
	c) if the device must be installed with or connected to other medical devices or equipment in order to operate as required for its intended purpose, sufficient details of its characteristics to identify the correct devices or equipment to use in order to obtain a safe combination;	NA			
	d) all the information needed to verify whether the device is properly installed and can operate correctly and safely, plus details of the nature and frequency of the maintenance and calibration needed to ensure that the devices operate properly and safely at all times;	NA			
	e) where appropriate, information to avoid certain risks in connection with implantation of the device;	NA			
	 f) information regarding the risks of reciprocal interference posed by the presence of the device during specific investigations or treatment; 	NA			
	g) the necessary instructions in the event of damage to the sterile packaging and, where appropriate, details of appropriate methods of re-sterilisation	A	EN ISO15223-1 EN1041	Product usage instruction	ОК

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	28 of 43

Checklist according to annex I of the Medical		A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
 h) if the device is reusable, information on tallow reuse, including cleaning, disinfect appropriate, the method of sterilization resterilized, and any restriction on the nut. Where devices are supplied with the interpret before use, the instructions for cleaning a that, if correctly followed, the device requirements in Section I). If the device bears an indication that the information on known characteristics and the manufacturer that could pose a rist re-used. If in accordance with Section 13 needed, the information must be made request; 	tion, packaging and, where on of he device to be mber if reuses. ention that they be sterilized and sterilization must be such will still comply with the he device is for single use, d technical factors known to sk if the device were to be .1 no instructions for use are	NA			
i) details of any further treatment or handli can be used (for example, sterilisation, fin		NA			
 j) in the case of devices emitting radiation of the nature, type intensity and distributio The instruction for use must also include staff to brief the patient on any contra-indi to be taken. These details should cover in 	n of this radiation details, allowing the medical cations and any precautions	NA			
 k) precautions to be taken in the event of of the device; 	changes in the performance	NA			

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for single use	Revision	Rev. A/0
	Page	29 of 43

Checklist	according to annex I of the Medical Device Directive (MDD)	A/ NA	Standards, other directives and other rules applied by manufacturer	Documentation (test reports, protocols, literature or reason for no applicability)	Ok or failure
fo	recautions to be taken as regards exposure, in reasonably oreseeable environmental conditions, to magnetic fields, external ctrical influences, electrostatic discharge, pressure or variations in essure, acceleration, thermal ignition sources etc.;	NA			
whie	adequate information regarding the medicinal product or products ch the device in question is designed to administer, including any tations in the choice of substances to be delivered;	NA			
	precautions to be taken against any special, unusual risks related to disposal of the device;	NA			
	nedicinal substances, or human blood derivatives incorporated into device as an integral part in accordance with Section 7.4;	NA			
p) d	legree of accuracy claimed for devices with a measuring function.	NA			
q) d	late of issue or the latest revision of the instructions for use.	А		The edition No. of the usage instruction	ok

CE Technical File- Sterile insulin
syringes for single use

File No	DM/QJ-CE-007
Revision	Rev. A/0
Page	30 of 43

8 Risk Analysis

Identification of qu	alitative and q	uantitative	characteristics	(acc.to EN ISC) 14971:2012, cl. 4.2)
----------------------	-----------------	-------------	-----------------	----------------	------------------------

Questions	Answer
C.2.1 What is the intended use and how is the medical device to be used?	Used for human body injection immediately after insulin medicine aspiration.
C.2.2 Is the medical device intended to be implanted?	NO.
C.2.3 Is the medical device intended to be in contact with the patient or other persons?	Yes, contact with the patient, surgically invasive devices intended for transient use
C.2.4 What materials or components are utilized in the medical device or are used with, or are in contact with, the medical device?	The product is a jacket, the stem's mainly raw material is polypropylene, the sheath's raw material is polyethylene, the piston's raw materials is natural rubber.
C.2.5 Is energy delivered to or extracted from the patient?	NO.
C.2.6 Are substances delivered to or extracted from the patient?	According to the patient's situation, supply, nutrient solution
C.2.7 Are biological materials processed by the medical device for subsequent re-use, transfusion or transplantation?	NO.
C.2.8 Is the medical device supplied sterile or intended to be sterilized by the user, or are other microbiological controls applicable?	Yes. The medical device supplied sterile and it is EO Sterilization
C.2.9 Is the medical device intended to be routinely cleaned and disinfected by the user?	NO.
C.2.10 Is the medical device intended to modify the patient environment?	NO.
C.2.11 Are measurements taken?	NO.
C.2.12 Is the medical device interpretative?	NO.
C.2.13 Is the medical device intended for use in conjunction with other medical devices, medicines or other medical technologies?	NO.
C.2.14 Are there unwanted outputs of energy or substances?	NO.
C.2.15 Is the medical device susceptible to environmental influences?	Avoid high temperature & moisture. Keep away from dust and worms.
C.2.16 Does the medical device influence the environment?	NO.
C.2.17 Are there essential consumables or accessories associated with the medical device?	NO.
C.2.18 Is maintenance or calibration necessary?	NO.
C.2.19 Does the medical device contain software?	NO.
C.2.20 Does the medical device have a restricted shelf-life?	YES,3 years
C.2.21 Are there any delayed or long-term use effects?	NO.
C.2.22 To what mechanical forces will the medical device be subjected?	NO.

CE Technical File- Sterile insulin
syringes for single use

File No	DM/QJ-CE-007
Revision	Rev. A/0
Page	31 of 43

C.2.23 What determines the lifetime of the medical device?	Sterilization, product material
C.2.24 Is the medical device intended for single use?	YES. single use
C.2.25 Is safe decommissioning or disposal of the medical device necessary?	NO.
C.2.26 Does installation or use of the medical device require special training or special skills?	Using by trained doctors or nurses.
C.2.27 How will information for safe use be provided?	User Manual.
C.2.28 Will new manufacturing processes need to be established or introduced?	NO.
C.2.29 Is successful application of the medical device critically dependent on human factors such as the user interface?	NO.
C.2.29.1 Can the user interface design features contribute to use error?	
C.2.29.2 Is the medical device used in an environment where distractions can cause use error?	NO.
C.2.29.3 Does the medical device have connecting parts or accessories?	This product can be used with the needle.
C.2.29.4 Does the medical device have a control interface?	NO.
C.2.29.5 Does the medical device display information?	NO.
C.2.29.6 Is the medical device controlled by a menu?	NO.
C.2.29.7 Will the medical device be used by persons with special needs?	NO.
C.2.29.8 Can the user interface be used to initiate user actions?	NO.
C.2.30 Does the medical device use an alarm system?	NO.
C.2.31 In what way(s) might the medical device be deliberately misused?	NO.
C.2.32 Does the medical device hold data critical to patient care?	NO.
C.2.33 Is the medical device intended to be mobile or portable?	NO.
C.2.34 Does the use of the medical device depend on essential performance?	NO.

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for	Revision	Rev. A/0
single use	Page	32 of 43

No	Hazard	Identify havanda	R	Risk Evaluation		tion	Risk Reduction Measure	Evidence	NH	ALOR
	General	Identify hazards	S	0	D	RL	Risk Reduction Measure	Evidence	NH	ALOR
D2.	Energy Hazards									
1	Electricity	N/A								
2	Heat	N/A								
3	Mechanical force	N/A								
4	Ionizing radiation	N/A								
5	Non Ionizing radiation	N/A								
6	Electromagnetic fields									
7	Moving parts	N/A								
8	Suspended masses	N/A								
9	Patient support device failure	N/A								
10	Pressure(vessel rupture)	N/A								
11	Acoustic pressure	N/A								
12	Vibration	N/A								
13	Magnetic fields(e.g. MRI)	N/A								
D3.	Biological hazards									
1	Bio-contamination	Contaminated packaging or damaged packaging	9	1	3	27	Single use and package control	Bacteria test report of the initial pollution	N	Acc.
2	Bio-incompatibility	The product may cause the user uncomfortable if the material is not OK	2	4	1	8	Choose raw materials of fabrics with qualified biological properties	See test report		Acc
3	Incorrect formulation(chemica I composition)	The product may cause the user uncomfortable if the material is not OK	2	3	1	6	Choose safe chemical raw material in recognize to ensure that the ingredients are accurate.	See test report		Acc
4	Toxicity	Toxic materials	9	1	2	18	Choose raw materials of fabrics with cyto toxicity meeting the requirements	See test report	N	Acc

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for	Revision	Rev. A/0
single use	Page	33 of 43

No	Hazard	Identify bogonda	R	isk E	valua	tion	Risk Reduction Measure	Evidence	NH	ALOR
	General	Identify hazards	S	0	D	RL	Risk Reduction Measure	Evidence	NП	ALOK
5	Allergenicity	N/A								
6	Mutagenicity	N/A								
7	Oncogenicity	N/A								
8	Teratogenicity	N/A								
9	Carcinogenicity	N/A								
10	Re-and/or cross-infection	Cross-infection caused by repeated use	2	3	2	12	Ensure that the products are for single use shall be shown on the instruction of use and labels.	Instruction of use and Labels	N	Acc.
11	Pyrogenicity	Environment,people,work-dimension alapparatus,ptocesswater,excessive, micro-organisms	2	3	1	6	Ensure that microb content in the production environment meets the requirements.	Verification, testing reports,	N	Acc.
12	Inability to maintain hygienic safety	Contamination of tan materials Initial pollution, heat	8	1	4	16	Ensure that microb content in the production environment meets the requirements.	Products operating instructions	N	Acc.
13	Degradation	N/A								
D4.	Environmental haza	ards and contributory factors						·		
1.	Electromagnetic fields	N/A								
2.	Inadequate supply of power or coolant	N/A								
3.	Susceptibility to electromagnetic interference	N/A								
4.	Emissions of electromagnetic interference	N/A								
5.	Inadequate supply of power or coolant	N/A								
6.	Inadequate supply of coolant	N/A								

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for	Revision	Rev. A/0
single use	Page	34 of 43

No	Hazard	Identify hazards	R	isk E	valua	tion	Risk Reduction Measure	Evidence	NH	ALOR
	General	Identify hazards	S	0	D	RL	KISK Reduction Measure	Evidence	МП	ALOK
7.	Storage or operation outside prescribed environmental conditions	N/A								
8.	Incompatibility with other devices	N/A								
9.	Accidental mechanical damage	N/A								
10.	Contamination due to waste products and /or device disposal	N/A								
D5.	Hazards resulting fro	om incorrect output of energy and s	ubs	tanc	es					
1.	Electricity	NA								
2.	Radiation	NA								
3.	Volume	NA								
4.	Pressure	NA								
5.	supply of medical gases	NA								
6.	supply of anaesthetic agents	NA								
D6.	Hazards related to th	e use of the device and contributor	y fa	ctor	S					
1	Inadequate labeling	The inadequate labeling may cause misuse.	2	2	1	4	Strengthen amending the label for warning	Refer to label.		Acc
2	Inadequate operating instructions	The inadequate operating instructions may cause misuse.	2	2	1	4	Strengthen amending the operating instructions.	See instruction of use		Acc
2.1	Inadequate specification of accessories	N/A								
2.2	Inadequate	The device may be damaged.	2	2	1	4	To strengthen pre-use	See		Acc

OF Tasky is al File. Otavila in audin syminana fan	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for	Revision	Rev. A/0
single use	Page	35 of 43

No	Hazard	Identify hazards	Risk Evaluation		tion	Risk Reduction Measure	Evidence	NH	ALOR	
	General		S	0	D	RL	NISK NEUUCIIOII IVIEASUIE	Evidence	1111	ALOK
	specification of pre-use checks						checks.	instruction of use		
2.3	Over-complicated operating instructions	N/A								
2.4	Inadequate specification of service and maintenance	N/A								
3	Use by unskilled/untrained personnel	The device may be damaged.	2	3	1	6	To strengthen training	See the instruction of use		Acc.
4	Reasonably foreseeable misuse	NA								
5	Insufficient warning of side effects	N/A								
6	Inadequate warning of hazards likely with re-use of single use devices	Cross-infection caused by repeated use of products					Warning statement on the note	Check the statement on the packaging	N	Y
7	Incorrect measurement and other metrological aspects	NA								
8	Incompatibility with consumables/accessori es/other devices	N/A								
9	Sharp side	NA								
D7.	Complicated operation	on								
1	Mistakes and judgement errors	NA								
2	Lapses and cognitive recall errors	NA								

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for	Revision	Rev. A/0
single use	Page	36 of 43

No	Hazard		R	Risk Evaluation		tion		E 1	NUT	AL OD
	General	Identify hazards	S	0	D	RL	Risk Reduction Measure	Evidence	NH	ALOR
3	Slips and blunders (mental or physical)	NA								
4	Violation or abbreviation of instructions, procedures, etc.,	NA								
5	Complex or confusing control system	NA								
6	Ambiguous or unclear device state	NA								
7	0Ambiguous or unclear presentation of settings, measurements or other information	NA								
8	Mispresentation of results	NA								
9	Insufficient visibility, audibility or tactility	NA								
10	Poor mapping of controls to action, or of displayed information to actual state	NA								
11	Controversial modes or mappings as compared to existing equipment	NA								
D8.	Hazards arising fro	m functional failure, maintenance a	and a	igeir	ng					
1	Erroneous data transfer	NA								

OF Taskying File Otavila in culin syminana fan	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for	Revision	Rev. A/0
single use	Page	37 of 43

No	Hazard	Identify hererds	R	isk E	valua	ation	Risk Reduction Measure	Evidence	NH	ALOR
	General	Identify hazards	S	0	D	RL	KISK REDUCTION MEasure	Evidence	INFI	ALUK
2	Lack of , or inadequate specification for maintenance including inadequate specification of post maintenance functional checks	The device may not work well if lack of inadequate post maintenance of functional checks	2	3	1	6	Strengthen post maintenance and functional checks	See instruction of use.		Acc
3	Inadequate maintenance	N/A								
4	Lack of adequate determination of end of device life	N/A								
5	Loss of mechanical integrity	N/A								
6	Inadequate packaging(contamin ation and /or deterioration of the device)	Pollution caused by the damaged packaging, and make patient infected	8	1	0	0	Do not use if the packaging is damaged	Statement on the packaging	N	Acc.
7	Re-use and / or Improper re-use	Pollution caused by damaged Seal	8	1	0	0	Do not use if the packaging is leakage	Statement on the packaging	N	Acc.
8	Deterioration in function (e.g. gradual occlusion of fluid/gas path, or change in resistance to flow, electrical conductivity) as a result of repeated	NA								

	File No	DM/QJ-CE-007
CE Technical File- Sterile insulin syringes for	Revision	Rev. A/0
single use	Page	38 of 43

No	Hazard	Identify hogonda	Risk Evaluation		tion	Disk Deduction Massure	Evidence	NH	ALOD	
	General	Identify hazards	S	0	D	RL	Risk Reduction Measure	Evidence	NП	ALOR
	use.									
B2.	2. Additional hazards to in vitro diagnostic medical devices									
1	Batch inhomogeneity, batch-to-batch inconsistency	NA								
2	Common interfering factors	NA								
3	Carry-over effects	NA	[
4	Specimen identification errors	NA								
5	Stability problems (in storage, in shipping, in use, after first opening of the container)	NA								
6	Problems related to taking, preparation and stability of speciments	NA								
7	Inadequate specification of prerequisites	NA								
8	Inadequate test characteristics	NA								

CE Technical File- Sterile
insulin syringes for single use

File No	DM/QJ-CE-007
Revision	Rev. A/0
Page	39 of 43

Abbreviations us	ed
RE	Risk Evaluation
S	Severity (9 –very severe, 0 –not severe)
0	Occurrence (9 –often, 0 –never)
D	Detection
	(9 –impossible to detect before risk occurs,
	0 -will be certainly detected before risk occurs)
RL	Risk Level = Severity × Occurrence × Detection
	1-9: Neglectable risk, no further actions;
	9-24: Moderate: minimal risk, preventive action recommended;
	25-48: Moderate risk, preventive action required;
	>48: Risk is usually not acceptable
RRM	Risk Reduction Measure
NH	New hazard generated (no/ yes - if yes, then number of new
	hazard indicated)
ALOR	Acceptable Level of Risk

Conclusion:

The report analyze the overview, product description, intended use, instruction for use, considerations, identification of characteristics related to the safety of the medical device, hazards that may exists, risk evaluation standard, residual risk evaluation, and evaluation on production and post-production information of single-use sterile stomach catheter according to the requirements of ISO14971 and "Risk Management Control Procedure", the drawn conclusion is that the risk of Sterile Insulin Syringes for single use can be reduced to an acceptable level in clinics after taking pertinent measures.

insulin syringes for single use

File No	DM/QJ-CE-007		
Revision	Rev. A/0		
Page	40 of 43		

9 Test Report

The product was manufactured and inspected by our company which carried out biocompatibility test by third party inspection institute. The quality management system established and conformity assessment has been audited by TUV Rheinland.

10 Sterile method and validation

The product was manufactured and sterilized by using Ethylene Oxide according to EN ISO 11135: 2014. The factory has established quality management system and its conformity assessment has been audited by TUV Rheinland.

11 Packaging verification

The product is single packed. To ensure the effectiveness of the packaging after sterilization, our company conducted the packaging verification test. All data demonstrates conformity with requirements of EN ISO 11607. The factory has established quality management system and its conformity assessment has been audited by TUV Rheinland.

12 Clinical evaluation

To prove the safety and effectiveness of the product, our company conducted the clinical evaluation. All data demonstrates conformity with relevant essential requirements and risks associated with the use of the device are acceptable when weighed against the benefits to the patient. The factory has established quality management system and its conformity assessment has been audited by TUV Rheinland.

13 Control Procedure of Vigilance System

Company set up vigilance procedure based on MDD 93/42/EEC.

5.1 Purpose

To reduce the re-occurrence of the similar accidents in different places at different times, to improve the safety and health protection of patients of users, to assess all reported accidents and issue information likely for the prevention of the re-occurrence of the similar accidents or alleviate the accidents results.

Scope

Applicable to the dealing of medical device accidents caused by all products with CE mark within CE territory.

Responsibility

5.2 CE authorized representative shall contact timely with the administration concerned and the company involved upon the receipt of accident report.

3.2 Distributor shall timely deliver the customer complaints and accident report to company and be responsible for protecting the record of sales.

5.3 Safety engineer shall be responsible for collecting the accident information and delivering it to all functioning departments and reversely delivering the measures of the accident taken by company to distributor and CE authorized representative and, to patients or user when necessary.

. Procedure

5.4 Business section shall timely report safety engineer upon the receipt of information of accident report from CE authorized representative, distributor and user. Safety engineer shall call in personnel concerned to discuss and analyze the information delivered. Once any of the following points is determined, administration concerned and company involved shall be reported to.

5.4.1 Type of accident, significant accident (e.g. patients died or state of illness severely

CE Technical File- Sterile

File No	DM/QJ-CE-007		
Revision	Rev. A/0		
Page	41 of 43		

insulin syringes for single use

deteriorated.

5.4.2 Whether the accident is related with company product. In the case of such accident is directly related with company product, report to the administration of the country where accidents happened, whereas, no report is needed but record shall be placed and reason be recorded.

5.4.3 Whether the accident arises any hindrance or possibly aroused by the information defects (e.g. insufficient or incorrect contents of instruction of use) of the company or products. If such defects did bring the accident, report to the administration of the country where accidents happened, whereas, no report is needed but record shall be placed and reason be recorded.

5.5 Accidents which shall be reported to the administration of the country where accidents happened

5.5.1 Accident that caused the death of patients or user

5.5.2 Accident that severely damaged the health of patients or user

Disease or damage that severely threaten life

Damage to body function or permanent damage to body structure

Loss of body function or permanent damage of body structure can only be prevented by means of medical means or operation.

5.5.3 Death or severely-deteriorating health will be caused under normal conditions but fortunately have not develop into accident (ready accident)

5.6 Material shall be reported

5.6.1Opinions of doctors (based on the obtained evidence)

Preliminary evaluation result provided by company;

Evidence of former similar accident;

Other evidence held by company.

5.6.2 Material regarding accident includes:

Product performance and major malfunction or deteriorating status of the performance;

No product failure or deterioration. But in the case of certain property may lead to accident, report it as a ready accident;

The instructions for use for the product are not so specified, or have neglects or shortages. 5.6.3 Report the materials regarding the accident along with the accident

5.7 Preliminary reporting time of accident or potential accident

5.7.1 Safety engineer present fundamental report within the following time upon the receipt of accident notice and submit it to legal organization through CE representative.

Accident : within 10 days.

Potential accident (ready accident): within 30 days.

5.8 Administration bureau of medical device that shall be reported to

5.8.1 Report to the national administration bureau where the medical device accident happened if in CE member countries.

5.8.2 If not in CE member countries

For Class I or above Class I, report to the country's the administration bureau where the notification institutes;

For Class I device, report to the country's administration bureau where the CE authorized representative is.

5.8.3 When appropriate, under the vigilance system, company shall inform the authorization representative and representatives of other bodies of accident reporting. At the same, company shall report to the notification institute.

5.9 Recall of Medical Device

5.9.1 The decision of recalling all of the medical devices in terms of technical or medical problems is notified to administration bureau concerned by company through CE

CE Technical File- Sterile

DM/QJ-CE-007		
Rev. A/0		
42 of 43		

insulin syringes for single use

authorized representative.

5.9.2"Advisory Notice" shall be issued when recalling products and be sent to administration bureau concerned.

5.9.3 Safety engineer organized personnel for collecting authentic materials and are authorized with the final decision-making right of notice issuing and product recalling.

5.10 Product recalling shall be reported to legal body

5.10.1 Safety engineer, in compliance with the requirements in annex of "Vigilance System Rules for Medical Device" submit the preliminary report to the legal institute of the country where accident happened through CE authorized representative.

5.10.2For device of Class I or above, if the quality accident happened not in CE member country and resulted the adopting of corrective action, such accident report shall be submitted to and notified the legal institute of the country concerned.

5.11 The detailed contents of the preliminary report shall be filled in "preliminary accident report"; make an analysis whether risk mitigating measures leads to new hazard.

5.12 Work after Preliminary Report

5.12.1 Safety engineer together with CE authorized representative shall investigate the accident according to preliminary report and report the process timely to legal institute.

5.12.2 If company is unable to investigate the accident, such situation shall be reported to legal institute without any delay.

5.13 Investigation Result and Corresponding Measures

5.13.1 Company takes appropriate measures subject to investigation result, e.g. consult with legal institute, recall product, etc.

5.13.2 Safety engineer, with the help of CE authorized representative, fill in the Final Accident Report which shall include the investigation result and appropriate measures taken and be submitted to legal institute by CE representative.

5.13.3 Appropriate measures as below after investigation shall be included:

No measures and reason of no measures;

Test and follow up the device under use;

Provide the user with information, e.g. issue notice (advisory notice)

Take action on successive products;

Recall product

5.14 Contact CE Authorized Representative about Detailed Rules

5.14.1 To guarantee the amendment to company technology document and the issue of medical device notice, CE authorized representative shall be noted with the effective ways of documents or other issues specified in the agreement signed by CE representatives.

5.14.2 Safety engineer shall fax any amendment to company document in no time to CE authorized representative and send it to CE representatives within on e week.

OF Technical File Otenile	File No	DM/QJ-CE-007	
CE Technical File- Sterile	Revision	Rev. A/0	
insulin syringes for single use	Page	43 of 43	

S/N	Changed section	What was changed	Revision number	Change person	Approval person	Change date
	/	Initial edition	A/0	/	/	/